INDIANAPOLIS, June 13, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising clinical activity in patients…
Welcome to the Healthcare Insights Desk at TheUnplanned.in, where we delve deep into the world of health and wellness. Our dedicated team of writers brings you authoritative articles, expert opinions, and insightful analyses on all facets of healthcare.
Discover more from The Unplanned
Subscribe to get the latest posts sent to your email.
